Impact of body mass index on long-term all-cause mortality after percutaneous coronary intervention in African-Americans

Journal of Invasive Cardiology

Volumn 21, Issue 1, 2009, Pages 20-25

  Poludasu, Shyam ^a   Cavusoglu, Erdal ^a   Khan, Waqas ^a   Marmur, Jonathan D ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

African Americans; Body mass index; Percutaneous coronary intervention

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BODY MASS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; SURVIVAL RATE;

AFRICAN AMERICANS; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; OBESITY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 60149085896     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity is an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-977.
2. Minutello RM, Chou ET, Hong MK, et al. Impact of body mass index on in-hospital outcomes following percutaneous coronary intervention (report from the New York State Angioplasty Registry). Am J Cardiol 2004;93:1229-1232.
3. Gurm HS, Brennan DM, Booth J, et al. Impact of body mass index on outcome after percutaneous coronary intervention. Am J Cardiol 2002;90:42-45.
4. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: The obesity paradox?. J Am Coll Cardiol 2002;39:578-584.
5. Oreopoulos A, Padwal R, Norris CM, et al. Effect of obesity on short- and long-term mortality postcoronary revascularization: A meta-analysis. Obesity (Silver Spring). 2008;16:442-450.
6. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-1555.
7. Marmur JD, Poludasu S, Agarwal A, et al. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention. J Invasive Cardiol 2006;18:521-526.
8. Marmur JD, Poludasu S, Agarwal A, et al. High-dose tirofiban administered as bolus-only during percutaneous coronary intervention. J Invasive Cardiol 2008;20:53-58.
9. Marmur JD, Poludasu S, Feit A, et al. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention. J Invasive Cardiol 2008;20:323-327.
10. Curb JD, Ford CE, Pressel S et al. Ascertainment of vital status through the National Death Index and the Social Security Administration. Am J Epidemiol 1985; 121:754-766.
11. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002;102:1893-1900.
12. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991;115:256-265.
13. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863.
14. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
15. Lincoff AM, Kleiman NS, Kereiakes DJ, et al for the REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs. heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703.
16. Gurm HS, Whitlow PL, Kip KE, Investigators B. The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization. J Am Coll Cardiol 2002;39:834-840.
17. Gruberg L, Mercado N, Milo S, et al. Impact of body mass index on the outcome of patients with multivessel disease randomized to either coronary artery bypass grafting or stenting in the ARTS trial. Am J Cardiol 2005;95:439-444.
18. Powell BD, Lennon RJ, Lerman A, et al. Association of body mass index with outcome after percutaneous coronary intervention. Am J Cardiol 2003;91:472-476.
19. Marmur JD, Poludasu S, Lazar J, Cavusoglu E. Long-term mortality after bolus-only administration of abciximab, eptifibatide or tirofiban during percutaneous coronary intervention. Catheter Cardiovasc Interv (in press).
20. Gottlieb SS. Dead is dead - artificial definitions are no substitute. Lancet 1997;349:662-663.
21. Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research: Time for a reassessment? J Am Coll Cardiol 1999;34:618-620.